Monitoring of circulating monocyte HLA-DR expression in a large cohort of intensive care patients: relation with secondary infections

C. de Roquetaillade1,7**, C. Dupuis2, V. Faivre3, A. C. Lukaszewicz4, C. Brumpt5 and D. Payen6†

Abstract

Introduction: The reports of an early and profound acquired immunodepression syndrome (AIDs) in ICU patients had gained sufficient credence to modify the paradigm of acute inflammation. However, despite several articles published on AIDs and its assessment by monocytic HLA-DR monitoring, several missing informations remained: 1—Which patients’ are more prone to benefit from mHLA-DR measurement, 2—Is the nadir or the duration of the low mHLA-DR expression the main parameter to consider? 3—What are the compared performances of leukocytes’ count analyses (lymphocyte, monocyte).

Material and method: We conducted an observational study in a surgical ICU of a French tertiary hospital. A first mHLA-DR measurement (fixed flow cytometry protocol) was performed within the first 3 days following admission and a 2nd, between day 5 and 10. The other collected parameters were: SAPS II and SOFA scores, sex, age, comorbidities, mortality and ICU-acquired infections (IAI). The associations between mHLA-DR and outcomes were tested by adjusted Fine and Gray subdistribution competing risk models.

Results: 1053 patients were included in the study, of whom 592 had a 2nd mHLA-DR measurement. In this cohort, 223 patients (37.7%) complicated by IAI. The initial decrement in mHLA-DR was not associated with the later occurrence of IAI, (p = 0.721), however, the persistence of a low mHLA-DR (< 8000 AB/C), measured between day 5 and day 7, was associated with the later occurrence of IAI (p = 0.01). Similarly, a negative slope between the first and the second value was significantly associated with subsequent IAI (p = 0.009). The best performance of selected markers was obtained with the combination of the second mHLA-DR measurement with SAPSII on admission. Persisting lymphopenia and monocytopenia were not associated with later occurrence of IAI.

Conclusion: Downregulation of mHLA-DR following admission is observed in a vast number of patients whatever the initial motif for admission. IAI mostly occurs among patients with a high severity score on admission suggesting that immune monitoring should be reserved to the most severe patients. The initial downregulation did not preclude the later development of IAI. A decreasing or a persisting low mHLA-DR expression below 8000AB/C within the first 7 days of ICU admission was independently and reliably associated with subsequent IAI among ICU patients with performances superior to leukocyte subsets count alone.

Keywords: Septic shock, ICU immunodepression, Innate immunity, HLA-DR, Intensive care patients, Immune monitoring

Introduction

The frequent reports of an early and profound acquired immunodepression syndrome (AIDs) in ICU patients had gained sufficient credence to modify the paradigm
of acute inflammation [1]. Even the definition remains debated, the quite constant element is a severe alteration of antigen-presenting cells (APC) to present the antigen to lymphocytes [1]. The association of altered lymphocyte absolute number with a reduction of their functional panel is frequently associated [2–4]. If the mechanisms are not fully elucidated at a molecular level, its detection can be accurately made by different methods such as ex vivo stimulation and cytokine response [5], ex vivo assessment of PBMCs' phagocytic capabilities [6] and longitudinal monitoring of circulating monocytes HLA-DR (mHLA-DR) [5, 7, 8]. Despite numerous articles published on AIDs with a mHLA-DR reduction including in severe COVID-19 [9, 10], several missing informations can be obtained only on a large cohort of ICU patients admitted for different diagnoses, using a homogenous flow cytometry protocol to measure mHLA-DR. The present retrospective study aimed to answer the following question: 1—Which patients' typologies are more prone to benefit from mHLA-DR measurement, 2—Is the nadir or the duration of the low mHLA-DR expression the main parameter to consider? 3—what is the real link between low mHLA-DR and the occurrence of secondary infections? Solving these issues might help clinicians to decide what patient would have to be monitored [11] and potentially to be stimulated using available drugs (interferon γ anti-PD-1, GMCSF, IL-7) [12, 13] for untreatable opportunistic infections [11]. The clarification of these questions is essential to validate the role of immune dysfunction and to design clinical trials to test the benefit of additional immunomodulatory therapies.

Material and methods

This study was approved by Cochin Hospital Ethics Committee (# CCPPRB 2061, Assistance Publique Hôpitaux de Paris). The mHLA-DR blood tests did not require the patient's informed consent since it was a retrospective study with routine measurements in our institution performed on the remaining routine blood samples, with a guarantee to use the data after their anonymization, according to the Ethical French law.

Study design and population

The cohort of patients was collected on the patients' database admitted in our center between 2013 to 2015 having routine measurements of HLA-DR, to evaluate the meaning of mHLA-DR monitoring. The only criteria used to select the cohort was to have had at least one measurement of mHLA-DR performed within the first 3 post ICU admission days. Patients hospitalized for less than 3 days, moribund, or treated with a chronic treatment by immunosuppressive drugs were excluded. Based on the motif for admission, 4 main clusters of life-threatening conditions were observed: (1) sepsis, defined by the criteria of the American College of Chest Physicians/Society of Critical Care Medicine [14]; (2) neurologic disorders, related to acute brain injury such as hemorrhagic or ischemic stroke; isolated severe brain trauma; post-neurosurgery; (3) major surgery (abdominal, orthopedic, ENT); (4) miscellaneous etiologies including primary respiratory failure, hemorrhagic shock from gastrointestinal bleeding or obstetric emergencies. IAI was diagnosed using the classic definition [15, 16]; a new-onset infection starting at least 48 h after ICU admission, which motivated a new antimicrobial therapy. The likelihood of infection motivating the clinical decision to administer antibiotics was classified as none, possible, probable, and definite [15]. Details of the classification method are provided in the e-Method section of Additional file 1. At the time of secondary infection diagnosis, the in-charge physician was not aware of the mHLA-DR value. Two senior intensivists (first and last author) blindly reviewed all patients' medical charts and adjudicated all secondary infections. In case of discordance, a third expert settled the final diagnosis (CD).

Circulating monocyte HLA-DR measurements (mHLA-DR)

The quantification of the expression of HLA-DR on monocytes was assessed using the number of antibodies per cell (AB/C) by flow cytometry (FACS Canto II instrument, FACS Diva software, Becton Dickinson, San Jose, CA USA) as previously described [7] (see detailed protocol in the e-method section of Additional file 1). In our center, the median and IQ range of mHLA-DR expression in healthy people for the measurements at the same period (n = 13) was a median log mHLA-DR value of 40,134 (IQR: 36,315–44,353). The first blood sample and measurement of mHLA-DR were performed within the first 3 days after admission. The 2nd measurement of mHLA-DR was obtained on fixed days (Monday or Thursday) until the patient's discharge or death. Since we used a survival model, only measurements sampled before the event were considered for analyses, and data were blinded at the time of the event (death or IAI). We used the threshold of AB/C < 8000 to define "low mHLA DR" corresponding to the acquired immune suppression as previously reported (NCT02361528) and because it corresponded to the median value observed in previously published datasets [7, 12]. Only the first nosocomial infection was considered for analysis.

Statistical analysis

The data were described as number and percentage for categorical variables and median (interquartile range (IQR)) for continuous variables. Comparisons relied on the Fisher exact test or χ² test for categorical data and
the Kruskal–Wallis or Wilcoxon test for continuous data. Because of non-linearity, all the mHLA-DR values were log-transformed. Age and SOFA scores were categorized based on the median value. A p-value of less than 0.05 was considered statistically significant.

Standard survival analyses are affected by the time of onset of the event of interest. Patients who have not experienced the event at the end of follow-up were censored. To determine the risk of an event occurring at a certain time-point, a fundamental assumption is that such censoring is not associated with an altered chance of the event occurring at any given moment. In this study, the event of interest is the occurrence of nosocomial infections and followed up until day 28 or until leaving alive from ICU. Indeed, death and leaving alive from ICU are competing events since, by definition, extubation precludes the observation of a ventilator-associated infection [17]. For that purpose, the association between mHLA-DR measurements and outcomes was assessed using adjusted Fine and Gray subdistribution competing risk models [18]. We first took into account the competing ICU discharge for the subdistribution hazard of mHLA-DR measurements on death at day 28. The subdistribution hazard of mHLA-DR measurements on the occurrence of IAI at day 28 was made considering the competing ICU death and ICU discharge. For each model, risk factors for the different outcomes were first researched by univariate analyses. The covariates tested into the models were the following: age, motif of admission, SOFA on day 1, comorbid conditions, and immune suppression. Although parenteral nutrition and the use of a central venous catheter are usual risk factors for NI, they were excluded from the predictors of NI. Almost every patient was managed with a central venous catheter, and enteral nutrition only was given to our patients. Then, the variables yielding p-values < 0.2 in univariate analysis were entered into a multivariate model using a backward selection, with p < 0.05 considered significant. The mHLA-DR measurement was forced into all the models. Results were expressed as subdistribution hazard ratios (sHR) with their 95% confidence intervals (95% CIs).

To analyze other immune factors possibly associated with IAI, we performed the same analyses using lymphocyte count (with lymphopenia defined as lymphocyte count 1000/mm³) and monocyte count (with monocytopenia defined as monocyte count below 500/mm³).

We assessed the robustness of our findings using multiple sensitivity analyses. We performed internal validation using a bootstrapping procedure, which was done by taking a large number of samples of the original one. This technique provides nearly unbiased estimates of the confidence intervals (CI) of the odds ratio (OR) of the independent covariates. Second, we performed logistic regression sensitivity analysis. Third, we used a multivariate cause-specific survival model. Fourth, we analyzed previous immune suppression as a comorbid condition and included age into the model. Fifth, we provide sensitivity analyses focusing on documented secondary infections and more specifically for secondary infections occurring at least 48 h after the second mHLA-DR measurement. Similar testing was applied for the VAP. All analyses were performed using SAS software, version 9.4 (SAS Institute Inc., Cary, North Carolina).

Results

Description of the cohort

Among the screened 1766 patients admitted in our ICU during the study period, 1053 patients benefited from a measurement of mHLA-DR within first days of admission. Among them, 592 patients benefited from a second measurement and were included for secondary infection analyses (for flowchart, see Additional file 1: Fig. S1). Motifs for admission were: isolated brain injury (n = 384, 36.5%); sepsis (n = 255, 24.2%); major surgery (n = 80, 7.6%); miscellaneous diagnoses (n = 334, 31.7%) (Table 1). Overall, ICU-mortality was 14.3% (n = 151). One episode IAI was diagnosed in 223 patients (37.7%) (Table 1) with a median delay from admission of 7 days (IQR [5; 11]). Secondary infections were mostly VAP (n = 126, 56.5%), abdomen nosocomial infections (peritonitis, biliary tract) (n = 40, 17.9%) and bacteremia/catheter-related infections (n = 35, 13.3%). The rate of these IAI was higher after major surgery (n = 28, 48.8%) and brain injury (n = 109, 43.95%) than after sepsis (n = 54, 31.8%, p < 0.01) (Additional file 1: Table S1).

mHLA-DR measurement at presentation

The 1st mHLA-DR expression median value was 9.2 log (IQR 8.7–9.7), with an average delay for measurement of 2 [1; 3] days. The number of patients having a low mHLA-DR < 8000 AB/C at baseline (defined as the threshold for low mHLA-DR) was 38.3% (n = 403). mHLA-DR expression values for all clusters were lower than those obtained from healthy volunteers and was observed among all prespecified subgroups of admission (Fig. 1). mHLA-DR downregulation was associated with initial severity assessed by the SAPS II, R² = −0.28 (IC95% [−0.34 to −0.23], p < 0.01).

Relation between mHLA-DR kinetic and later occurrence of IAI

A second mHLA-DR measurement was performed in 592 of the 1053 patients (Table 1). Those patients were mainly admitted for brain injury (n = 248, 41.9%) and sepsis (n = 170, 28.7%). In this cohort, the initial
Table 1  Characteristics of the global cohort and patients having 2 measurements of mHLA-DR

| Parameters, n (%) or median [IQR] | All patients (n = 1053) | Patients with two mHLA-DR measurement (n = 592) |
|-----------------------------------|-------------------------|-----------------------------------------------|
| Age 59.3 [44.8; 71.8] | 59.8 [46.5; 71.4] |
| Sex (female) 444 (42.2) | 236 (39.9) |
| Comorbid condition | | |
| Hypertension 399 (37.9) | 197 (39.6) |
| Cardiac insufficiency 233 (22.1) | 100 (20.1) |
| Immunosuppression 229 (21.7) | 94 (18.9) |
| Diabetes 155 (14.7) | 81 (16.3) |
| Respiratory failure 98 (9.3) | 46 (9.3) |
| Chronic kidney disease 91 (8.6) | 39 (7.8) |
| Cirrhosis 47 (4.5) | 17 (3.4) |
| Diagnostic on admission | | |
| Sepsis 255 (24.2) | 170 (28.7) |
| Septic shock (classic definition) 77 (7.3) | 72 (42.4) |
| Origin of the infection | | |
| Cutaneous 83 (32.5) | 61 (35.9) |
| Respiratory 65 (25.5) | 46 (27.1) |
| Abdominal 61 (23.9) | 36 (21.2) |
| Neurologic 15 (5.9) | 11 (6.5) |
| Urinary 18 (7.1) | 9 (5.3) |
| Others 13 (5.1) | 7 (4.1) |
| Neurologic admission 384 (36.5) | 248 (41.9) |
| Subarachnoid hemorrhage 103 (26.8) | 75 (30.2) |
| Brain Traumatism 68 (17.7) | 49 (19.8) |
| Intra cranial hemorrhage 68 (17.7) | 42 (16.9) |
| Neurological surgery 63 (16.4) | 32 (12.9) |
| Ischemic stroke 50 (13) | 27 (10.9) |
| Subdural hematoma 18 (4.7) | 10 (4) |
| Others 17 (4.4) | 13 (5.2) |
| Post-surgical care | | |
| Abdominal 59 (73.8) | 33 (80.5) |
| ORL 8 (10) | 5 (12.2) |
| Orthopedics 8 (10) | 2 (4.9) |
| Others 5 (6.3) | 1 (2.4) |
| Miscellaneous 334 (31.7) | 133 (22.5) |
| Hemorrhagic shock 67 (20.1) | 30 (22.6) |
| Respiratory failure from a medical origin 79 (23.7) | 27 (20.3) |
| Polytrauma 37 (11.1) | 25 (18.8) |
| Medical abdominal disease 31 (9.3) | 13 (9.8) |
| Obstetrical 24 (7.2) | 6 (4.5) |
| Cardiac arrest 13 (3.9) | 5 (3.8) |
| Others 83 (24.9) | 27 (20.3) |
| Severity on admission | | |
| Day 1 SAPS II (miss = 6) 37 [25; 50] | 39 [28; 51] |
| Day 1 SOFA (neuro excluded) (miss = 6) 4 [2; 7] | 5 [2; 8] |
| HLA-DR Cell count measurements | | |
| Delay from admission to mHLA-DR measurement, days (1st/2nd) 2 [1; 3] | 2 [1; 3/5] [4; 7] |
| Log mHLA-DR (1st/2nd) 9.2 [8.7; 9.7] | 9.1 [8.7; 9.6/9.2] [8.7; 9.6] |
| Low mHLA-DR, < .000 AB/C (1st/2nd) 403 (38.3) | 253 (42.7) [221 (37.3)] |
The decrement in mHLA-DR was not associated with the later occurrence of IAI, after adjustment for confounding factors ($p = 0.721$) (Fig. 2). However, the persistence of a low mHLA-DR ($< 8000$ AB/C), measured between day 5 and day 7, was associated with the later occurrence of IAI ($p = 0.01$). Similarly, a negative slope between the first and the second value was significantly associated with subsequent IAI ($p = 0.009$). When SAPS II was combined with the negative mHLA-DR slope, IAI incidence was higher than with each component alone (Fig. 3).

In the cause-specific multivariate model (Table 2), the first measurement of mHLA-DR $< 8000$ AB/C was not associated with subsequent secondary infection (cs-HR 1.02 [0.7; 1.48], $p = 0.93$), however, a decreasing slope between first and second mHLA-DR measurement was associated with subsequent occurrence of secondary infection (cs-HR 1.53 [1.06; 2.19], $p = 0.02$). The combination of a first low mHLA-DR and decreasing slope was strongly associated with later occurrence of secondary infection (cs-HR 1.73 [1.07; 2.82], $p = 0.03$). Lymphopenia within the first days of admission was associated with

### Table 1 (continued)

| Parameters, $n$ (%) or median [IQR] | All patients ($n = 1053$) | Patients with two mHLA-DR measurement ($n = 592$) |
|------------------------------------|---------------------------|-------------------------------|
| Leucocytes, $10^9$/L (1st/2nd)     | 10.8 [8.5; 14.4]          | 11.1 [8.9; 15.1]/11 [8.6; 4.5] |
| Neutrophils, $10^9$/L (1st/2nd)    | 8.5 [6.4; 11.8]           | 9 [6.6; 12.5]/8.6 [6.2; 11.7] |
| Lymphocytes, $10^9$/L (1st/2nd)    | 1.3 [0.9; 1.7]            | 1.2 [0.8; 1.7]/1.3 [1; 1.8]   |
| Monocytes, $10^9$/L (1st/2nd)      | 0.7 [0.5; 1]              | 0.8 [0.5; 1.1]/0.8 [0.6; 1.1] |

Outcomes

- Delay before 1st ICU-acquired infection (days) 7 [5; 10.5] 7 [5; 11]
- Number of ICU-acquired infections 245 (23.3) 223 (37.7)
- Source of ICU-acquired infection
  - Respiratory 138 (13.1) 126 (21.3)
  - Abdominal 44 (4.2) 40 (6.8)
  - Bacteremia, catheter-related 40 (3.8) 35 (5.9)
  - Others 23 (2.2) 22 (3.7)
- ICU length of stay 7 [4; 14] 13 [8; 22]
- Delay before death 6 [3; 14] 13 [8; 25]
- ICU death 151 (14.3) 79 (13.3)
- Early death, (~ day 7, $n = 1040$) 82 (7.9) –
- Late ICU death (among patients alive at day 7, $n = 499$) 60 (12)

IQR: interquartile; ICU: Intensive Care Unit; SAPS: Simplified Acute Physiology Score; SOFA: Sequential Organ Failure Assessment; NLCR: neutrophil-to-lymphocyte count ratio; mHLA-DR: monocytic human leukocyte antigen-antigen D related; AB/C: antibody per cell. For diagnostic at admission, data are expressed as percentage within the subgroups.

**Fig. 1** Initial mHLA-DR measurement according to the motif of admission and initial severity, comparison with controls. Low mHLA-DR expression is defined by a level $< 8000$AB/C
the later occurrence of IAI, this was not the case for its persistence nor the decrease in lymphocyte count during ICU stay. The decreased monocyte count was negatively associated with delayed occurrence of IAI (cs-HR = 0.66 [0.47; 0.92], \( p = 0.02 \)). Overall, the best performance of selected markers was obtained with the combination of
Since the second measurement of mHLA-DR may be influenced by the acquired infection itself particularly if not yet detected, we performed a sensitivity analysis focusing on IAI occurring at least 48 h after last mHLA-DR measurement (Additional file 1: Table S5). Among the 458 patients identified for this analysis, a decrement in mHLA-DR (decreasing slope) remained associated with later development of IAI (HR = 2.16, IC95% [1.39–3.36], p < 0.01). Analysis focusing on documented NI (n = 251/276) retrieved similar results (HR = 1.86, IC95% [1.27; 2.74], p < 0.01) for mHLA-DR < 8 000 AB/C and HR = 1.57, IC95% [1.07; 2.29], p = 0.02 for decreasing slope). However, association between mHLA-DR value or kinetic and subsequent VAP was not significant (HR = 1.19, IC95% [0.66; 2.16], p = 0.56 for mHLA-DR < 8 000 AB/C and HR = 1.66, IC95% [0.96; 2.86], p = 0.07 for decreasing slope).

### Table 2 Multivariate cause-specific survival model: sensitivity analysis of predictors of secondary infection occurrence

| Variable | Cs-HR | IC95% | p     |
|----------|-------|-------|-------|
| Log mHLA-DR1 | 0.90  | [0.67; 1.19] | 0.46  |
| Low mHLA-DR1 | 1.06  | [0.72; 1.57] | 0.77  |
| Log mHLA-DR2 | 0.63  | [0.48; 0.81] | 0.00  |
| Low mHLA-DR2 | 1.75  | [1.21; 2.53] | 0.00  |
| Slope (%) | 0.98  | [0.97; 0.99] | 0.00  |
| Slope (↘) | 1.61  | [1.13; 2.3]  | 0.01  |
| Low mHLA-D1 and down slope | 1.95  | [1.17; 3.26] | 0.01  |
| Lymphopenia 1 | 1.62  | [1.13; 2.32] | 0.01  |
| Lymphopenia 2 | 0.87  | [0.58; 1.3]  | 0.51  |
| Lymphopenia down | 0.98  | [0.69; 1.41] | 0.93  |
| Monocytopenia 1 | 0.94  | [0.65; 1.34] | 0.71  |
| Monocytopenia 2 | 0.59  | [0.41; 0.85] | 0.00  |
| Monocytopenia down | 0.66  | [0.47; 0.92] | 0.02  |

The cause-specific model is a common alternative to survival analysis for handling competing risks. This model allows a quantification of the cause-specific relative hazard, which is the association between the exposure and the outcome when the individuals with the competing event are censored.

The following covariates were used: comorbidities (without immunosuppression), immunosuppression, SOFA score and motif of admission.

The competing event was “discharged alive before 28 days” and the outcome was nosocomial infection.

### Discussion

**Key results**

In this observational monocentric large cohort of ICU patients, the monitoring of mHLA-DR during the first-week post-admission showed a strong association between persisting low expression of mHLA-DR and the further development. An early mHLA-DR downregulation was observed in a large proportion of patients whatever the initial motif for admission suggesting a common pathway of resilience to aggression [19, 20]. The clear correlation between the severity at admission and the depth of mHLA-DR downregulation indicates that such monitoring might be indicated for the most severe patients.

Our study supports the interest to repeat the monitoring of mHLA-DR expression during the first post-admission days to identify the patients at risk for IAI with a threshold of 8000 AB/C to define an ICU-acquired immune suppression when consensus protocol for measurement is applied.

**Interpretations**

The steps for generalization of immune biomarkers to identify ICU patients at risk of complications as IAI require large cohorts and validation by randomized clinical trials. We and others have previously reported similar results in reasonable cohorts of ICU patients, mostly septic [7, 8, 10, 21, 22]. The present study confirms these previous results and investigated different ICU contexts, including septic, surgical and neurologic patients [7]. Altogether these findings confirm the adapted early downregulation of mHLA-DR (as a resilience mechanism) [19, 20] to maintain the tissue fitness and limit the consequences of acute inflammation. Conversely to most previous reports, our analyses was made after adjustments for confounding factors as severity and occurrence of IAI as potential downregulating mHLA-DR. Moreover, it took into account the comorbid conditions, particularly the previous immune suppression. The present study highlights the risk of a persisting mHLA-DR downregulation as a marker of immune suppression and its association with the increased vulnerability to IAI [1]. The other markers proposed to diagnose AID had a limited reproducibility and performance when compared to HLA-DR [22]. In addition, these markers necessitate specific human skills to be performed and are not feasible on a day-to-day basis to help for clinical decision. In the present study, the leucocyte absolute number especially the lymphocytes absolute number were not as informative as mHLA-DR was. A recent article reports...
the longitudinal testing of injury-induced immune profile changes (30 immune biomarkers) in a large cohort of ICU patients [23]. Except for T cell and CD4 T cell absolute number, none of the 30 markers were significantly different between sepsis, trauma or surgical groups, suggesting a “universal phenomenon”, which does not depend on the type of injury as reported for HLA-DR [7]. Among the leading markers, CD74 mRNA and mHLA-DR seemed to have the best performance to assess an IAI in relation with secondary infection. Interestingly, mHLA-DR+S1009A were the best predictors for secondary infection. Such “multimodal immune monitoring approach” deserves further prospective study to tailor the immunomodulating therapies.

The perspective of such immune monitoring is to objectively help the clinician to characterize the innate immunity and the immune synapse with adaptive immunity, to characterize the AID and to propose to stimulate innate immunity, as reported previously [12]. The persistence of AID associated with IAI despite adequate antimicrobial therapy may then justify using immunostimulating drugs as it was shown in recent articles [12, 24–27]. Enrolling the adequate patients in the future clinical trials will then benefit from such immune monitoring, markedly the mHLA-DR that fits well to the requirements of ICU clinical context. Based on our observation, we can suggest that immune monitoring should be reserved to the most severe patients.

Limitations
The current study has, however, some limitations. First, it is a monocentric evaluation, which hampers the generalization of the results to all centers. Second, no other immune parameters, such as cytokines plasma levels or NK cells, or Treg lymphocytes have been measured. Even with this limitation, this was coherent with our choice for routine immune monitoring in the “real life” in our center. Third, based on our results, no prospective cohort of patients has been used to prospectively test the validated parameters. We try to limit this aspect by the use of the bootstrap statistical method, which confirmed the primary analysis. Some limitations might also be seen as advantages. The care protocols were more homogenous within one center and the measurement of mHLA-DR was stable for the protocol and rigorously measured following the European task force [28]. The technical variation in the measurements may then result only from the manual steps of the protocol, which will be solved by the development of automated devices. The collected cohort covered clinical contexts with systemic inflammation in the “real life” corresponding to our recruitment with limited exclusion. To our knowledge, the size of our cohort is the largest reported for now that confirmed previous results obtained in smaller cohorts [7, 10]. The occurrence of an early AID was observed in the vast majority of the ICU patients [7, 8, 29]. The deliberate choice to not consider the patients dying before day 4 post-admission was coherent with the goal of the study. The blood sampling for mHLA-DR as early as the first 2 days was useful for testing the kinetic of evolution as this potential marker to predict IAI, which was shown to be relatively stable within the first 4 post-admission days [10].

When considering only VAP, mHLA-DR value and kinetic was not associated with subsequent VAP (p = 0.07). Several assumptions may be made to explain such results. Diagnosis of VAP is very difficult, and may be missed by both clinical examination and radiological exam. Several studies have acknowledged important inter-observatory variability in the diagnosis of ICU-acquired infection. Despite the use of external review and CDC criteria, as in our case, postmortem studies comparing VAP diagnosis with clinical criteria showed 69% sensitivity and 75% specificity, in comparison to autopsy findings [30]. On the contrary, diagnosis of bacteremia and/or post-surgery infection is less debatable. VAP also carries a specific pathophysiology which not only relies on immunological factors, but also on local factors (micro-inhalation, reintubation, exposure to ventilator), which unfortunately, could not be taken into account in our model.

Conclusion
A rapid decrease in mHLA-DR within the first days following admission is observed in a vast number of patients whatever the initial motif for admission. Initial down-regulation of mHLA-DR correlates with the severity on admission suggesting that immune monitoring should be applied to the most severe patients. The initial decrement in mHLA-DR does not preclude the later development of IAI, whereas a decreasing or a persisting low mHLA-DR expression below 8000 AB/C within the first 7 days of ICU admission was independently and reliably associated with subsequent IAI among ICU patients. The performance of these parameters is superior to leukocyte subsets count alone.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13613-022-01010-y.

Additional file 1. Supplementary material comprises e-method, flow chart and sensitivity analyses

Author contributions
Cdr and DP conceived the study, analyzed data and wrote the manuscript. CD analyzed data, wrote the manuscript and performed statistical analysis. ACL,
References

1. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13:862–74.
2. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol. 2001;166:6952–63.
3. Hotchkiss RS, Swanson PE, Freeman BD, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med. 1999;27:1230–51.
4. Monneret G, Venet F, Pachot A, et al. Monitoring the immune dysfunction risk-stratify critically ill patients: INFECT study. Curr Opin Immunol. 2013;25:477–83.
5. Monneret G, Lepape A, Miatte J, et al. Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series. BMC Infect Dis. 2019;19:931.
6. Döcke W-D, Höflich C, Davis KA, et al. Monitoring temporary immunodepression in septic patients. J Infect Dis. 2016;214:16045.
7. Grimaldi D, Pradier O, Hotchkiss RS, et al. Nivolumab plus interferon-γ in septic shock. Curr Opin Crit Care. 2016;22:16045.
8. Venet F, Teixeira C, Fleury M. IFN-γ therapy in septic shock: potential new therapeutic option. Crit Care. 2011;15:1.
9. Roquilly A, Godefroy L, Girard Y, et al. Monitoring the immune dysfunction risk-stratify critically ill patients: INFECT study. Curr Opin Immunol. 2013;25:477–83.
10. de Roquetaillade C, Mansouri S, Brumpt E, et al. Comparison of circulating immune cell profiles and kinetics between coronavirus disease 2019 and bacterial sepsis. Crit Care Med. 2021. https://doi.org/10.1097/CCM.000000000005088.
11. Jung B, Le Bihan C, Portales P, et al. Monocyte human leukocyte antigen-DR but not β-d-glucan may help early diagnosing invasive Candida infection in critically ill patients. Ann Intensive Care. 2021;11:129.
12. Payen D, Faivre V, Miatte J, et al. Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series. BMC Infect Dis. 2019;19:931.
13. Volk H-D, Reinke P. To be, or not to be immunocompetent. Crit Care. 2013;17:185.
14. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med. 2003;29:S30–8.
15. Calandra T, Cohen J. The International Sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med. 2005;33:1538.
16. Gaynes RP. Surveillance of nosocomial infections: a fundamental ingredient for quality. Infect Control Hosp Epidemiol. 1997;18:475–8.
17. Wolkewitz M, Cooper BS, Bonten M, et al. Interpreting and comparing risks in the presence of competing events. BMJ. 2014;349:g5060.
18. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
19. Medzhitov R, Schneider DS, Soares MP. Disease tolerance as a defense strategy. Science. 2012;335:936–41.
20. Chen GY, Núñez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010;10:826–37.
21. Conway Morris A, Datta D, Shankar-Hari M, et al. Cell-surface signatures of immune dysfunction risk-stratify critically ill patients: INFECT study. Intensive Care Med. 2018;44:627–35.
22. Cajander S, Rasmussen G, Tina E, et al. Dynamics of monocytic HLA-DR expression differs between bacterial etiologies during the course of bloodstream infection. PLoS ONE. 2018;13:e0192883.
23. Venet F, Textors J, Blein S, et al. Immune Profiling demonstrates a common immune signature of delayed acquired immunodeficiency in patients with various etiologies of severe injury. Crit Care Med. 2021. https://doi.org/10.1097/CCM.0000000000005270.
24. Hotchkiss RS, Sherwood ER. Getting sepsis therapy right. Science. 2015;347:1201–2.
25. Venet F, Lukaszewicz A-C, Payen D, et al. Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies. Curr Opin Immunol. 2013;25:477–83.
26. Hotchkiss RS, Moldawer LL, Opal SM, et al. Sepsis and septic shock. Nat Rev Dis Primers. 2016;2:16045.
27. Grimaldi D, Pradier O, Hotchkiss RS, et al. Nivolumab plus interferon-γ in the treatment of intractable mucormycosis. Lancet Infect Dis. 2017;17:18.
28. Döcke W-D, Höflich C, Davis KA, et al. Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem. 2005;51:2341–7.
29. Monneret G, Lepape A, Venet F. A dynamic view of mHLA-DR expression in management of severe septic patients. Crit Care. 2011;15:1.
30. Fabregas N, Ewig S, Torres A, et al. Clinical diagnosis of ventilator associated pneumonia revisited: comparative validation using immediate post-mortem lung biopsies. Thorax. 1999;54:867–73.